CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies

Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im

Cancer Research and Treatment. 2023;55(3):766-777. Published online 2023 January 19 DOI: https://doi.org/10.4143/crt.2022.987

Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies

Yong Wha Moon, Seung Ki Kim, Keun Seok Lee, Moon Hee Lee, Yeon Hee Park, Kyong Hwa Park, Gun Min Kim, Seungtaek Lim, Seung Ah Lee, Jae Duk Choi, Eunhye Baek, Hyesun Han, Seungjae Baek, Seock-Ah Im

Cancer Research and Treatment. 2023;55(3):766-777

Link1

Link2 Link3

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

Patrick Wayne Cobb, Yong Wha Moon, Klára Mezei, István Láng, Gajanan Bhat, Shanta Chawla, Steven J. Hasal, Lee S. Schwartzberg

Cancer Medicine. 2020;9(17):6234-6243

Link1 Link2 Link3 Link4

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz, Ildiko Aradi

BMC Cancer. 2019;19(1):

Link1

Link2 Link3

Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin

K. Horvat-Karajz, D. Grecea, M. Smakal, A. Illes, Z. Kahan

Annals of Oncology. 2017;28:v555

Link1 Link2 Link3

Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia

A.-R. WALADKHANI

European Journal of Cancer Care. 2004;13(4):371-379

Link1 Link2

Efficacy and safety of pegteograstim and pegfilgrastim on chemotherapy-induced neutropenia in ovary cancer patients

M.K. Kim

Gynecologic Oncology. 2020;159:357

Link1 Link2

Risk of febrile neutropenia as a function of age and disease stage in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management – results from the NeuCuP analysis

M. Aapro, M. Schwenkglenks, G. Lyman, A. Lopez-Pousa, P. Bacon, S. Lawrinson, G. Von Minckwitz

European Journal of Cancer Supplements. 2008;6(7):195-196

Link1 Link2

2033 ORAL Improved chemotherapy delivery in breast cancer patients receiving pegfilgrastim primary prophylaxis compared with current practice neutropenia management – results from an integrated analysis (NeuCuP)

M. Aapro, M. Schwenkglenks, G. Lyman, A. Lopez-Pousa, V. Easton, T. Skacel, G. Von Minckwitz

European Journal of Cancer Supplements. 2007;5(4):194

Link1 Link2

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda, Toshimi Takano, Toshiaki Saeki, Seigo Nakamura, Ryutaro Shimazaki, Yoshinori Ito, Yutaka Tokuda, Kazuo Tamura

Supportive Care in Cancer. 2015;23(4):1137-1143

Link1

Link2 Link3 Link4

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia

Derek Weycker, Richard L. Barron

Cancer. 2010;116(12):3073-3073

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.